On November 11, 2024, Charles F. Wagner Jr., Executive Vice President and Chief Financial Officer of Vertex Pharmaceuticals Inc (VRTX, Financial), sold 3,000 shares of the company. The transaction was documented in a recent SEC Filing. Following this sale, the insider now owns 44,137 shares of Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals Inc, headquartered in Boston, Massachusetts, is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has a strong focus on developing and commercializing therapies for the treatment of cystic fibrosis and advancing research and development programs in other areas of high unmet medical need, including pain, rare diseases, and hematology.
Over the past year, Charles F. Wagner Jr. has sold a total of 15,500 shares and has not purchased any shares of the company. This recent sale is part of a broader trend seen within the company, where there have been 59 insider sells and no insider buys over the past year.
Shares of Vertex Pharmaceuticals Inc were trading at $518.27 on the day of the sale. The company has a market cap of approximately $127.38 billion. According to the GF Value, the intrinsic value of the stock is estimated at $393.71, indicating that the stock is modestly overvalued with a price-to-GF-Value ratio of 1.32.
The GF Value is calculated based on historical multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, adjusted for the company’s past performance and expected future business results as estimated by Morningstar analysts.
This insider sale comes at a time when the stock is perceived as modestly overvalued based on fundamental analysis metrics. Investors and stakeholders in Vertex Pharmaceuticals Inc may want to consider the broader insider selling trend and valuation metrics when making investment decisions.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
